CTTQ
Status and phase
Conditions
Treatments
About
This is a Phase Ib clinical trial to evaluate the safety and efficacy of TQB2450 injection combined with AL2846 capsules in patients with advanced solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Age 18~75 years old; Eastern Cooperative Oncology Group (ECOG) score: 0~1 point; Expected survival is more than 3 months;
Subjects diagnosed by histopathological or cytology with hepatocellular carcinoma or gastric adenocarcinoma/adenocarcinoma of the gastroesophageal junction or non-small cell lung cancer or urothelial carcinoma or esophageal squamous cell carcinoma;
Patients with hepatocellular carcinoma need to meet the following criteria at the same time:
Patients with advanced gastric adenocarcinoma/gastroesophageal junction adenocarcinoma who are not suitable for surgery and who have failed first-line standard chemotherapy (treatment of not less than 2 cycles) must meet any of the following criteria:
Central nervous system (CNS) metastasis with no clinical symptoms or is accompanied by clinical symptoms, but the condition is controlled after treatment and the stability time is ≥ 4 weeks (subjects with central nervous system metastases need to be excluded from cohorts 4 and 6);
Subjects with advanced non-small cell lung cancer must meet the following conditions:
The previous treatment of patients with urothelial carcinoma meets any of the following:
Patients with advanced esophageal squamous cell carcinoma failure with previous immune checkpoint suppression agents such as PD-1/PD-L1;
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
135 participants in 6 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal